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Findings are based on 2,621 responses to Release’s ‘Coronavirus Drug Purchases Impact Survey’ received 
between the 9th April 2020 and the 17th September 2020 (inclusive). Responses capture drug purchases made 
in anticipation of and during the first UK national lockdown, as well as purchases made during the easing, 
and eventual lifting, of this first national lockdown. Individuals aged 18 and over, residing in the UK, were 
eligible to complete the online survey and respondents were asked to describe a recent drug purchase. 
• The majority of respondents did not report finding a supplier, or a desired drug, to be more 
difficult when comparing their experiences to before the start of the COVID-19 pandemic. 
However, difficulties in finding a supplier, and a desired drug, were more often reported as the 
first national lockdown eased and lifted – an observation consistent with supply shortages.
• More than 1 in 10 purchases were made on the darknet. Of these purchases, 13% had not 
previously used the darknet to buy drugs, and over a quarter of the sample stated that they 
planned to use the darknet to buy drugs if necessary, signalling a shift to darknet markets that 
may have been prompted by the pandemic.
• Reports of price(s) being higher than they were prior to the pandemic were more frequent than 
reports of prices being the same or lower. Higher prices were more often reported as the first 
national lockdown eased and lifted – an observation consistent with supply shortages.
• The majority of respondents reported that the purity of their purchase remained the same (and for 
some, actually increased). This is consistent with suppliers responding to drug shortages by increasing 
prices and perhaps reducing deal-sizes, as opposed to using adulterants to bulk out products. 
• Purchases of cannabis products were most commonly reported across all periods of the 
pandemic (7 in 10 purchases overall), as expected. We found relatively infrequent purchases 
of MDMA/ecstasy, and other drugs associated with going out/partying - consistent with fewer 
opportunities to socialise related to pandemic-related restrictions.
• In connection to almost two-thirds (62%) of drug purchases made during lockdown, respondents 
reported that their suppliers adhered to government-advised social distancing measures. There 
is evidence that some suppliers also adopted additional measures, similar to those adopted by licit 
markets (for example, accepting card payments and disinfecting cash), in order to further prevent 
virus transmission.
• More respondents reported that their drug use had increased, rather than decreased or stayed the 
same, since the start of the pandemic.
• When comparing their experiences to before the pandemic, more respondents reported increased 
contact with the police than reduced, or the same level of, contact with police.
• When comparing their experiences to before the pandemic, more respondents reported 
experiencing increased withdrawal symptoms, increased non-fatal overdoses, and increased 
injection equipment-sharing, than reduced, or the same level of, these harms.
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In the same way that the COVID-19 pandemic has profoundly impacted all aspects of our lives, it is reasonable to 
expect that with lockdowns and global restrictions on movement, the drug market will also be impacted.1 The European 
Monitoring Centre for Drugs and Drug Addiction has stated that there is “a critical need to investigate the impact of 
these developments on drug markets in order to identify changes that may require an immediate policy or operational 
response… and to learn lessons about how we might better anticipate emerging threats in the future”2
The availability of controlled drugs - whether bought via online platforms or via face-to-face transactions - will likely be 
compromised by COVID-19, particularly where those drugs are transported across borders.3 In anticipation of possible 
drug shortages, some people who use drugs may ‘stockpile’ their drugs of choice; contributing further to potential shortages.4 
Given a rapid shift to online purchasing of licit goods during the pandemic, we might expect a similar shift in respect to 
drug purchasing behaviour, with an increase in darknet purchasing.5 
Since the beginning of the first national coronavirus lockdown, Release has operated a public, online survey designed to 
monitor how people are buying their drugs. The purpose of this survey, which is open to anyone residing in the UK over the 
age of 18, is to determine the impact that the COVID-19 pandemic, and corresponding restrictions, have had on buying 
illegal substances. Release also set up a national ‘Drug Market Monitoring Network’, made up of people who use drugs, 
harm reduction and recovery activists, as well as people working on the frontline, who continue to regularly report on 
developments in their local drug markets during the pandemic.i Qualitative feedback from the Drug Market Monitoring 
Network will be used where appropriate to contextualise quantitative findings from the survey. 
In May 2020, Release updated Vice on survey results less than 2 months into the first national coronavirus lockdown. We 
noted that the market had remained relatively stable, but we predicted that we would see more change over the coming 
months, given that disrupted trade routes and production take time to impact destination markets (like the UK).6
In this current paper, we present findings from the 2,621 responses received between the survey’s launch on the 9th April 
2020 and the 17th September 2020 (inclusive); which capture drug purchases made in anticipation of and during the first 
national lockdown, as well as purchases made during the easing, and eventual lifting ii, of the first national lockdown.
i Reports from the ‘Drug Market Monitoring Network’ are also shared with Public Health England
ii A new phase of the first UK national lockdown was entered on the 4th July 2020 following a large number of restrictions being lifted. However, this was not 
uniform across the UK.
Introduction 
In Anticipation
Purchases made in anticipation of the first national lockdown:
Purchases before 23rd March 2020
During 
Purchases made during the first national lockdown:
Purchases between 23rd March - 10th May 2020
Eased
Purchases made when the first national lockdown eased:
Purchases between 11th May - 4th July 2020
Lifted
Purchases made when the first national lockdown was lifted across most of the UK:
Purchases between 5th July - 17th September 2020
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The survey obtained ethical approval from the University of Manchester. It is confidential and responses are anonymous, 
with no identifiable information, or IP addresses, being collected. The survey asks respondents to describe a recent drug 
purchase, including its date, location (UK region), drug type, price, and quantity, as well as how the respondent believes 
purchasing may be different compared to purchases made before the start of the COVID-19 pandemic. The survey asks 
respondents to comment on the difficulty associated with finding desired products and suppliers, perceived changes in 
product quality and price, and whether purchases were made via the darknet marketplaces. Respondents were able to 
complete the survey multiple times, and were encouraged to do so for subsequent drug purchases. Given the removal of 
IP addresses for respondent anonymity, it was not possible to identify how many individual respondents have completed 
the survey. The unit of analysis is therefore transactions (purchases), not buyers. The questions apply to drugs bought with 
money (including virtual currency) or obtained otherwise from someone as a gift or traded for non-monetary property. 
Key findings presented below are in connection to drug availability, quality and price, use of the darknet, supplier behaviour, 
and harm(s) experienced. More than half of the responses received (56%) were from 18-24-year-olds, with one quarter 
(25%) from 25-34-year-olds. Almost three-quarters of survey returns identified as male (69%), and the majority were 
in full time employment (32%). This broadly aligns with the sociodemographic characteristics of people who use drugs 
(PWUDs) as captured by the Crime Survey for England and Wales: which finds that drug use prevalence is higher among 










Drugs Purchased Drugs reported in the survey more than ten times are presented
* Cannabis includes: Sinsemilla/Skunk/Import, Herbal cannabis (low grade), Other cannabis, Cannabis resin/hash, Cannabis oil/shatter/extract 
** Psychedelics  include: LSD, 2CB, Mushrooms / DMT / other psychedelics
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As expected, when examining drug purchases overall (n = 2528, missing = 93), cannabis product purchases were most 
commonly reported to the survey - with 7 in 10 transactions connected to cannabis. There have also been reports from 
our national Drug Market Monitoring Network of suppliers and users moving to cannabis use/supply due to the restricted 
availability of other drugs. Cannabis resin is significantly less popular than herbal cannabis in the UK8, however we were 
surprised by the low proportion of reported cannabis resin/hash purchases (3% of purchases overall, 4% of cannabis product 
purchases) and this is supported by reports from our Drug Market Monitoring Network regarding a scarcity of resin. 
It is interesting to see more psychedelic drug purchases than MDMA/ecstasy purchases (6% and 4% of purchases overall, 
respectively). Previous national surveys have shown MDMA/ecstasy to be more popular than psychedelic drugs, for example, 
LSD.9 The low proportion of MDMA purchases, a substance that is associated with highly socialised environments such 
as clubs and festivals, is an expected response to the pandemic given reduced social interaction and fewer opportunities 
to use this drug in customary settings. We may find that this change is reflected in future national and international drug 
monitoring surveys. 
Reports of nitrous oxide (n=1) and synthetic cannabinoid (n=2) purchasing were negligible. Given nitrous oxide’s popularity 
among the largest response group to this survey, 18 to 24-year-olds – as recorded by national surveys10 - it will be important 
to see whether there has been a reduction in nitrous oxide use, reflected in future drug monitoring surveys, or whether this 
result reflects that in this transaction-based survey, people buying nitrous oxide did not consider this a drug purchase in 










Changes in drug use compared to ‘before the pandemic’  
Respondents were asked to report whether their drug use in general had increased, decreased, or stayed the same, in 
comparison to before the pandemic. Increased use was most commonly reported (43%), followed by reports that use had 
stayed the same (36%). About 1 in 5 respondents reported reduced drug use. 
When responses to the question of whether drug use had increased, reduced, or stayed the same were disaggregated 
by the type of drug purchased, reports of increased use were more common than reports of decreased use for all drug 
types. However, an increase in use was more pronounced for reported purchases of cannabis products (with the exception 
of cannabis resin/hash).  For the drugs most associated with going out/parties (MDMA, cocaine, ketamine), reporting 
reduced use was almost as common as reporting increased use. 
 (n = 2587) 
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Availability Indicators of drug availability compared to ‘before the pandemic’ 




































Finding a supplier was only reported as being ‘more difficult’ for a minority of the sample (between 29% and 41% over 
the period studied) compared to their experiences of drug purchasing before the pandemic. Reports of having difficulty 
increased slightly for drugs purchased during lockdown (31%) compared to purchases made in anticipation of lockdown 
(29%). However, reports of difficulty finding suppliers increased as lockdown eased (34%) and lifted (41%).  
Making a purchase from someone other than a ‘preferred’ supplier can be an indicator of reduced availability. Although 
a majority did not report doing so throughout the period of the survey, the minority who did increased from 22% for 
purchases made in anticipation of lockdown to 29% for purchases made during lockdown, and then increased again to 
33% and 41% for purchases made as lockdown eased and then lifted, respectively.
Finding the ‘drug wanted’ for the reported purchase was described as being more difficult  for a minority of the sample (less 
than 1 in 3). However, reports of finding the wanted drug being more difficult increased from around 20% (for purchases 
made in anticipation of and during lockdown), to 26% as lockdown eased, and to 30% after lockdown lifted. 
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We might anticipate that reduced drug availability results from: (1) scarcity of product arising from reduced opportunities 
for, and increased risks associated with, transporting products; and/or (2) increased risk of getting caught arising from 
official attention to dwindling numbers of citizens in public locations. Intelligence collected from the Drug Market 
Monitoring Network supports that rather than supply scarcity driving reduced drug availability during the early stages of 
lockdown, the increased risk of getting caught was likely to have played an important role. For example, some suppliers 
worked reduced hours, and at certain hours (usually during the day when there were more people out), in order to avoid 
detection. We have subsequently learnt that stop and search increased during the first national lockdown (discussed further 
within Individual and Social Harms, page 11), suggesting that the risk of detection may indeed have increased.
The reduced availability we observed during earlier stages of lockdown likely reflects increased risk of conducting drug 
transactions in public spaces. However, the fact that availability problems remain or indeed increase as lockdown began 
to ease suggests that supply scarcity played an increasing role. This possibility is supported by anecdotical evidence from 
the Drug Market Monitoring Network. During the early stages of lockdown, reports from the network suggested that 
suppliers were confident that they had enough stock for around three months – a period that broadly aligns with lockdown 
easing and lifting. This period also coincided with the well-publicised arrests connected to law enforcement access into the 
‘Encrochat’ encrypted messaging service used by many organised criminal groups focused on the supply of Class A drugs. 
Arrests following the Encrochat closure in June 2020 coincided with reports that the markets for cocaine, crack cocaine 
and heroin across the country were significantly disrupted.11 Whilst the present survey did not specifically ask questions 
about the Encrochat closure, the arrests made following its closure are thought to have had an impact on the supply of 
drugs alongside lockdown restrictions. 
Whilst it is important to note that the majority of purchases reported in the survey were made offline, our finding that 
over 1 in 10 purchases were made online via the darknet, means that we have captured a shift to darknet markets that may 
have been prompted by the COVID-19 pandemic.12 This may be motivated by actual or perceived shortages in local offline 
drug markets, or in connection to people spending more time at home, online, and with more available time to acquire the 
knowledge and skills required to access the darknet.
Google Trends analysis shows some increases in interest during the lockdown period as gauged by google searches using 
the terms ‘buy drugs online’, which have tended to spike more frequently over the period since the first national lockdown 
eased and lifted. Whilst the Drug Market Monitoring Network has not focused on darknet drug activity, there have been 
anecdotal reports of increased use by people seeking prescription drugs, particularly benzodiazepines, and of individuals 
‘offering to show others how to use the darknet for a fee’.
Use of the 
darknet Of these 291 purchases, 13% had not 
previously used the 
darknet to buy drugs
(1.5% of all purchases 
reported, n = 38)
11% of the sample (n = 291) 
reported purchases that had 
been made on the darknet. 
26% of the sample (n = 626) 
stated that they planned to use the 
darknet to buy drugs if the drug they 
sought was unavailable to them locally.
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Purchases made of products reported as having ‘the same’ purity/strength as ‘before the pandemic’ occurred for the majority, 
but decreased from 81% (for purchases made in anticipation of lockdown) to 75% during lockdown, to 66% as lockdown 
eased, and to 56% as lockdown was lifted. Interestingly, purchases made in the three periods prior to lockdown lifting were 
equally as likely to be higher purity/strength as lower purity/strength.  As lockdown lifted, however, purity/strength was 
more likely to be higher (25%) than lower (19%). 
Purchases made of products reported as having ‘the same’ price as ‘before the pandemic’ were most common; 74% for 
purchases made in anticipation of lockdown, dropping to around 70% for purchases made during lockdown and its easing, 
and dropping again to 67% as lockdown lifted. Reports of prices being higher exceed reports of lower prices, and by the 
time the national lockdown lifted, respondents were twice as likely to report higher than lower prices. This mirrors reports 
from the Drug Market Monitoring Network of increasing prices, particularly for cocaine and cannabis, and this fits our 
prediction that in situations of scarcity or increased risk of selling, price would increase, or purity-adjusted price would 
increase. 
As the majority of respondents reported that the purity of their purchase remained the same, and higher-than-expected 
purity reports increase over the period studied, this is indicative of suppliers responding to drug shortages by increasing 
prices and perhaps reducing deal-sizes, as opposed to using adulterants to bulk out products. These findings are also 
consistent with global reports of increased drug prices, and largely stable drug purity, as captured by the 2020 Global Drug 
Survey, which specifically sought to understand the global drug market response to COVID-19.13
Quality and price
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Supplier precautions during Lockdown  purchases made between 23rd March - 10th May 2020
Supplier precautions 
Steps taken by suppliers to reduce virus transmission
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Respondents were asked which, if any, safety practices their suppliers employed to reduce transmission of the virus in 
connection to a reported purchaseiii.
For purchases made during lockdown, for example, almost two-thirds of suppliers were reported to practice the two-metre 
social distancing rule (62%). In common with many supermarket chains at the time, 1 in 5 respondents reported that the 
supplier from whom the purchase was made would not accept cash, preferring for their customers to pay by bank transfer or 
PayPal (20%). Other techniques used to reduce transmission of the virus during drug transactions, as reported by respondents, 
included suppliers wearing gloves (38%) and suppliers having modified drug packaging (30%). These additional precautions 
adopted by suppliers challenge longstanding perceptions of suppliers as “morally bereft actors”.14 
Steps taken to reduce virus transmission were most commonly reported in connection to drugs purchased during lockdown, 
compared to drugs purchased as lockdown eased and lifted. One exception was found for suppliers wearing masks, which 
was highest for transactions taking place after lockdown lifted (35%). This is broadly reflective of the proportion of the 
general UK population who reported either ‘always or frequently’ wearing a mask (37%) outside of the home in the week 
commencing 6th July 2020 (as captured by the COVID-19 behaviour tracker15).
The general trend towards suppliers adopting fewer safety measures over the periods studied may reflect ‘lockdown 
fatigue’16 : confusion about which strategies may be most effective, or an evolving understanding of the mechanisms of virus 
transmission, which increasingly prioritised aerosol transmission over surface/touch transmission. The contrasting increase 
in suppliers’ use of face masks in the final period analysed here may reflect broader uptake and social accommodation of 
mask wearing more generally.
iii It is not known whether transactions occurred inside closed spaces or in open areas
Individual and social harms
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Respondents were asked to compare their current experience(s) to their experiences ‘before the pandemic’. Reports of 
overdosing ‘more often’ (39%) were more frequent than reports of overdosing less often (25%) when comparing experiences 
to before the coronavirus.  Respondents were substantially more likely to report that contact with the police happened 
more often (47%) than less often (26%).  Withdrawal was substantially more likely to be rated as more of a problem (51%) 
than less of a problem (14%). Reports of sharing injecting equipment more often (36%) were also slightly more frequent 
than reports of sharing injecting equipment less often (29%).
In addition to the risks that people who are drug-dependent face in terms of serious respiratory illness if they become 
infected with COVID-19 - due to the high prevalence of chronic medical conditions among this population17 - it is clear 
that the COVID-19 pandemic has brought additional risk(s) for people who use drugs. The present results indicate that 
individuals overall have experienced more withdrawal, more (non-fatal) overdoses, more contact with the police, and have 
engaged more frequently in risky needle sharing practices during the pandemic compared with prior to the pandemic.18
Whilst the pandemic has led to discovering new ways to provide harm reduction services, such as delivering or mailing 
supplies, extending prescription lengths,19 medicine hotlines for prescriptions, screening clients for COVID-19 symptoms 
in efforts to prevent transmission,20 as well as smaller initiatives such as Release’s own ‘essential-journey’ travel cards to assist 
in people’s journeys to services,21 more must be done to assist harm reduction services in their operations moving forward.
The increased contact with police reported here mirrors a concerning pattern of increased stop and search during the 
COVID-19 pandemic:22 with the vast majority of such searches being for drugs (over 60% of searches under the main 
police powers).23 During May 2020 alone, the Metropolitan Police Service conducted 43,913 searches: the highest monthly 
rate of the police’s use of these powers in London since January, 2012. Of these searches, 68% were for drugs.24 These 
searches were not linked to COVID-19 restrictions, or adherence with lockdown rules, but it is worth noting that these 
powers were most used in London boroughs suffering the highest rates of COVID-19 deaths.25
It is also important to note that a vast majority of responses to the present survey (92%) were from individuals identifying 
as ‘White’. We therefore expect, given the wealth of evidence to support disproportionate contact with police for ethnic 
minority individuals26, that the lack of BAME experiences captured is likely to have impacted the proportion of the sample 
reporting increased contact with police over the period studied.
Change in individual and social harms compared to ‘before the pandemic’
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The findings reported here help us better understand how the buying and selling of drugs in the UK may 
have changed as a result of the COVID-19 pandemic. This understanding informs the work that Release 
does in providing free, specialist advice and information to the public and professionals on issues related to 
drug use and drug laws - as well as the work done by other organisations represented in the Drug Market 
Monitoring Network. Our findings show that whilst COVID-19 has resulted in adaptations to practices 
involved in buying and selling drugs, the drug market itself has remained remarkably resilient in the face 
of such unprecedented restrictions, whilst harms to some of the people who use drugs have increased. 
Facilitating harm-reduction initiatives may therefore be more beneficial than continued efforts to control 
supply through law enforcement actions, which have limited impact on the supply of drugs and drug use.
As we enter subsequent lockdowns, and as the restrictions associated with the COVID-19 pandemic 
continue, it is vital that we continue to monitor the market via analyses of drug buying. The Coronavirus 
Drug Purchases Impact survey is still running. Please help us understand the impact of subsequent lockdowns 
by filling in the survey – and we encourage you to do this every time you purchase drugs so that we can see 
how things are changing.  You are also able to email us at drugreport@release.org.uk if you have insights into 
the market that would help us. The email is confidential.
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